Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Plus Prednisolone in Newly Diagnosed Immune Thrombocytopenia
NCT06531018Phase 2Recruiting
- Sponsor
- Renata
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in primary immune thrombocytopenia (ITP), sponsored by Renata. Started Feb 2025; status: recruiting.
02
Drugs
eltrombopag
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06531018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531018.